Effects of pregabalin on central sensitization in patients with migraine

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 4, 2015, Pages 277-283

  Zhang, Na ^a,b   Chen, Chun Fu ^a   Yu, Fei Yu ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Allodynia; Central sensitization; Migraine; Pregabalin

Indexed keywords

PREGABALIN; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT;

ADULT; AGED; ALLODYNIA; ALLODYNIA SYMPTOM CHECKLIST SCALE; ARTICLE; CENTRAL SENSITIZATION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE IMPACT TEST 6 SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDAS (MIGRAINE); MIGRAINE; NAUSEA; PAIN ASSESSMENT; RATING SCALE; SENSITIZATION; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA; ANALOGS AND DERIVATIVES; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHI SQUARE DISTRIBUTION; COMPLICATION; DRUG EFFECTS; HYPERALGESIA; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANALGESICS; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHI-SQUARE DISTRIBUTION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYPERALGESIA; LOGISTIC MODELS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929469905     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202205     Document Type: Article

References (32)

1. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia. 2004; 24 (Suppl 2): 2-7.
2. Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache. 2006; 46 (Suppl 4): S182-S191.
3. Ashkenazi A, Silberstein S, Jakubowski M, Burstein R. Improved identification of allodynic migraine patients using a questionnaire. Cephalalgia. 2007; 27: 325-329.
4. Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, Lipton RB, AMPP Group. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology. 2008; 70: 1525-1533.
5. Güven H, Çilliler AE, Çomoʇlu SS. Cutaneous allodynia in patients with episodic migraine. Neurol Sci. 2013; 34: 1397-1402.
6. Zappaterra M, Guerzoni S, Cainazzo MM, Ferrari A, Pini LA. Basal cutaneous pain threshold in headache patients. J Headache Pain. 2011; 12: 303-310.
7. Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interictally using a questionnaire? Neurology. 2005; 65: 1419-1422.
8. Pitcher GM, Henry JL. Cellular mechanisms of hyperalgesia and spontaneous pain in a spinalized rat model of peripheral neuropathy: changes in myelinated afferent inputs implicated. Eur J Neurosci. 2000; 12: 2006-2020.
9. Bauer CS, Rahman W, Tran-van-Minh A, Lujan R, Dickenson AH, Dolphin AC. The anti-allodynic alpha(2)delta ligand pregabalin inhibits the trafficking of the calcium channel alpha(2)delta-1 subunit to presynaptic terminals in vivo. Biochem Soc Trans. 2010; 38: 525-528.
10. Tuchman M, Barrett JA, Donevan S, Hedberg TG, Taylor CP. Central sensitization and Ca(V)α2δ ligands in chronic pain syndromes: pathologic processes and pharmacologic effect. J Pain. 2010; 11: 1241-1249.
11. Pizzolato R, Villani V, Prosperini L, Ciuffoli A, Sette G. Efficacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study. J Headache Pain. 2011; 12: 521-525.
12. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl 1): 9-160.
13. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999; 53: 988-994.
14. Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003; 12: 963-974.
15. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF; American Migraine Prevalence Prevention Advisory Group. Cutaneous allodynia in the migraine population. Ann Neurol. 2008; 63: 148-158.
16. Tfelt-Hansen P, Pascual J, Ramadan N, Dahlof C, D'Amico D, Diener HC, Hansen JM, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012; 32: 6-38.
17. Misra UK, Kalita J, Bhoi SK. Allodynia in migraine: clinical observation and role of prophylactic therapy. Clin J Pain. 2013; 29: 577-582.
18. Palmeira CC, Ashmawi HA, Posso IP. Sex and pain perception and analgesia. Rev Bras Anestesiol. 2011; 61: 814-828.
19. Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience. 2001; 106: 793-800.
20. Coppola G, Currà A, Di Lorenzo C, Parisi V, Gorini M, Sava SL, Schoenen J, Pierelli F. Abnormal cortical responses to somatosensory stimulation in medication-overuse headache. BMC Neurol. 2010; 10: 126.
21. Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, Waldemar G, Knudsen GM. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging. 2008; 29: 1830-1888.
22. Togsverd M, Werge TM, Tankó LB, Bagger YZ, Hansen T, Qin G, Christiansen C, Rasmussen HB. Association of a dopamine beta-hydroxylase gene variant with depression in elderly women possibly reflecting noradrenergic dysfunction. J Affect Disord. 2008; 106: 169-172.
23. Kelman L, Tanis D. The relationship between migraine pain and other associated symptoms. Cephalalgia. 2006; 26: 548-553.
24. Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs. 2003; 12: 663-672.
25. Calandre E P, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010; 33: 35-39.
26. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013; 6: CD010609.
27. Lau W, Dykstra C, Thevarkunnel S, Silenieks LB, de Lannoy IA, Lee DK, Higgins GA. A back translation of pregabalin and carbamazepine against evoked and non-evoked endpoints in the rat spared nerve injury model of neuropathic pain. Neuropharmacology. 2013; 73: 204-215.
28. Sałat K, Librowski T, Nawiesniak B, Gluch-Lutwin M. Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain. Neurol Res. 2013; 35: 948-958.
29. Chizh BA, Gohring M, Troster A, Quartey GK, Schmelz M, Koppert W. Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers. Br J Anaesth. 2007; 98: 246-254.
30. Stacey BR, Barrett JA, Whalen E, Phillips K F, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. The journal of pain: official journal of the American Pain Society. [Multicenter Study]. Randomized Controlled Trial. 2008; 9: 1006-1017.
31. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP, Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008; 12: 203-213.
32. Lyseng-Williamson KA, Siddiqui MA. Pregabalin: a review of its use in fibromyalgia. Drugs. 2008; 68: 2205-2223.